Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Rhea-AI Summary

Aytu BioPharma (Nasdaq: AYTU) announced management will present at NobleCon21 — Noble Capital Markets 21st Annual Emerging Growth Equity Conference in Boca Raton, FL.

The presentation is scheduled for Wednesday, December 3, 2025 at 10:30 AM ET. A high-definition webcast will be posted the following day on the company website and on Noble Conference and Channelchek, with the webcast archived for 90 days. Management will hold one-on-one investor meetings; scheduling via Noble representatives or aytu@lythampartners.com.

DENVER, CO / ACCESS Newswire / November 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that its management will participate at NobleCon21 - Noble Capital Markets' 21^st Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.

Management will be presenting on Wednesday, December 3rd at 10:30 a.m. Eastern time. A high-definition video webcast of the presentation will be available the following day on the Company's website (www.aytubio.com), and as part of a complete catalog of presentations available at Noble Capital Markets' Conference website (www.nobleconference.com) and on Channelchek (www.channelchek.com), the investor portal created by Noble. The webcast will be archived on the Company's website, the NobleCon website and on Channelchek for 90 days following the event.

Management will also be conducting one-on-one meetings at the conference. Investors should contact their Noble representatives, or Robert Blum of Lytham Partners at aytu@lythampartners.com, to schedule one-on-one meetings.

About Aytu BioPharma

Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD) and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.

Contacts for Investors

Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com

Robert Blum
Lytham Partners
aytu@lythampartners.com

SOURCE: Aytu BioPharma, Inc.

View the original press release on ACCESS Newswire

FAQ

When will Aytu BioPharma (AYTU) present at NobleCon21?

Aytu management will present on December 3, 2025 at 10:30 AM Eastern.

Where can I watch the AYTU presentation webcast from NobleCon21?

The high-definition webcast will be posted the next day on aytubio.com, NobleCon website, and Channelchek.

How long will Aytu's NobleCon21 webcast remain available online?

The webcast will be archived for 90 days on the company site, NobleCon site, and Channelchek.

Can investors schedule one-on-one meetings with Aytu management at NobleCon21?

Yes; investors should contact their Noble representative or email aytu@lythampartners.com to schedule meetings.

What topics will Aytu BioPharma (AYTU) cover at NobleCon21 presentations?

The company said management will present recent corporate developments and outlook; the webcast provides the complete presentation.